Statins and safety: can we finally be reassured?

摘要

Statins have revolutionised modern cardiovascular treatment by producing a striking reduction in coronary risk. In 2005, the Cholesterol Treatment Trialists' (CTT) collaboration reported a meta-analysis of 14 randomised trials (including about 90000 patients) of statin versus placebo that recorded a 20% relative risk reduction in major vascular events (comprising coronary death, non-fatal myocardial infarction, coronary revascularisation, or stroke) per 1 mmol/L decrease in LDL cholesterol.